Cargando…
PMON169 D2R Expression in Dopamine-Agonist Resistant Prolactinomas
INTRODUCTION: Dopamine-agonist (DA) resistant prolactinomas are characterized by failure to achieve normal prolactin levels or reduce tumor size by at least 50% on maximal conventional DA dosages. This occurs in about 10% of patients on cabergoline and is more common in larger macroadenomas, and in...
Autores principales: | Levine, Alice, Bass, Ilana, Alba, Eva, Umphlett, Melissa, Shuman, William, Milgrim, Emily, Milgrim, Lucas, Bederson, Joshua, Post, Kalmon, Shrivastava, Raj |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9625567/ http://dx.doi.org/10.1210/jendso/bvac150.1139 |
Ejemplares similares
-
PMON78 Improvement in Resistant Hypogonadism with use of Clomiphene in Prolactinomas Treated with Dopamine Agonist: A Case Study and Review of Literature
por: Singh, Julie, et al.
Publicado: (2022) -
SUN-448 Giant Prolactinomas: A Follow-Up of 25 Years with Dopamine Agonists
por: Mallea Gil, Susana, et al.
Publicado: (2019) -
SAT-247 Use of Double Dopamine Agonists in Giant Prolactinomas: A Series of 6 Cases
por: Kuan, Yueh Chien
Publicado: (2020) -
MON-293 The Prevalence of Impulse Control Disorders in Patients with Acromegaly and Prolactinomas Treated with Dopamine Agonists
por: Ozkaya, Hande Mefkure, et al.
Publicado: (2020) -
FRI303 PRL-R Variants Are Not Only Associated With Prolactinomas But Also With Dopamine Agonist Resistance
por: de Castro Moreira, Andrea Ramos, et al.
Publicado: (2023)